Next Issue
Volume 3, March
Previous Issue
Volume 2, September
 
 

Lymphatics, Volume 2, Issue 4 (December 2024) – 5 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
5 pages, 212 KiB  
Commentary
Ultrastaging and Low-Volume Metastatic Disease in Early-Stage Cervical Cancer: State of the Art
by Alejandro Soderini, Ignacio Macció, Alejandro Aragona, Florencia Arrudi, Baca Noel and Patricio Mollar Vigh
Lymphatics 2024, 2(4), 260-264; https://doi.org/10.3390/lymphatics2040020 - 23 Dec 2024
Viewed by 343
Abstract
The sentinel lymph node technique in early-stage cervical cancer—when to perform it, its process, as well as the surgical specimen—continues to be a challenge for gynecologists, oncologists, and pathologists in order to plan the therapeutic strategy. The objective of this paper is to [...] Read more.
The sentinel lymph node technique in early-stage cervical cancer—when to perform it, its process, as well as the surgical specimen—continues to be a challenge for gynecologists, oncologists, and pathologists in order to plan the therapeutic strategy. The objective of this paper is to describe the state of the art and provide a critical point of view about these topics. Full article
16 pages, 1593 KiB  
Review
Management of Secondary Immunodeficiency Following T-Cell-Engaging Immunotherapeutic Agents in B-Cell Non-Hodgkin Lymphoma: Implications for Early-Line Treatment Strategies
by William Grant Day, Jon Heald, Sierrah Grigsby, Peter Beale, Luke Pittman and Christin B. DeStefano
Lymphatics 2024, 2(4), 244-259; https://doi.org/10.3390/lymphatics2040019 - 7 Dec 2024
Viewed by 719
Abstract
Anti-CD19 chimeric antigen receptor (CAR) T-cell and anti-CD20 bispecific antibody therapies (BsAbs) are rapidly moving to earlier treatment lines for patients with B-cell non-Hodgkin lymphoma (B-NHL). The rapid pace of the advancement of these T-cell-engaging therapies is juxtaposed by a lack of a [...] Read more.
Anti-CD19 chimeric antigen receptor (CAR) T-cell and anti-CD20 bispecific antibody therapies (BsAbs) are rapidly moving to earlier treatment lines for patients with B-cell non-Hodgkin lymphoma (B-NHL). The rapid pace of the advancement of these T-cell-engaging therapies is juxtaposed by a lack of a comprehensive understanding of the scope and kinetics of immunodeficiency following these treatments. We review emerging studies detailing the safety and efficacy of CD19 CAR-T and CD20 BsAbs in earlier lines for B-NHL, as well as a discussion of the limited knowledge of immune recovery following these treatments. We integrate the limited consensus prevention and management recommendations, advocating that the management of secondary immunodeficiency following these transformative therapies is an urgent unmet need in immune oncology research. A collaboration between hematologists/oncologists and immunologists in the management of these patients is critical to optimize patient care. Full article
(This article belongs to the Collection Lymphomas)
Show Figures

Figure 1

16 pages, 2849 KiB  
Review
Endovascular and Percutaneous Lymphatic Interventions in Cancer Patients: A Review Article
by Mohanad Ghonim, Mohamed Ghonim, Ahmed K. Aly, Ernesto Santos and Amgad M. Moussa
Lymphatics 2024, 2(4), 228-243; https://doi.org/10.3390/lymphatics2040018 - 26 Nov 2024
Viewed by 827
Abstract
Lymphatic complications are becoming increasingly identified in cancer patients. Chylous ascites, chylothorax, lymphoceles, and lymphorrhea are common in cancer patients and can occur due to traumatic injury during surgeries or infiltrative effects of the tumors themselves. Recently, some anti-neoplastic medications are also thought [...] Read more.
Lymphatic complications are becoming increasingly identified in cancer patients. Chylous ascites, chylothorax, lymphoceles, and lymphorrhea are common in cancer patients and can occur due to traumatic injury during surgeries or infiltrative effects of the tumors themselves. Recently, some anti-neoplastic medications are also thought to result in lymphatic complications. Management options range from conservative options to minimally invasive interventions, to surgical interventions with no standardized management strategy. Imaging techniques such as dynamic contrast-enhanced magnetic resonance lymphangiography and intranodal computed tomography or fluoroscopic lymphangiography are becoming more valuable in diagnosis and treatment planning. Minimally invasive interventions are rapidly evolving and have become the first-line intervention in most cases. Current research, however, faces limitations due to study design and variability. Standardized reporting and prospective studies are needed to advance the field. This review summarizes some of the latest literature on lymphatic interventions in cancer patients and provides reporting recommendations for future studies on lymphatic interventions. Full article
Show Figures

Figure 1

16 pages, 2850 KiB  
Review
The Current State of Lymphedema Surgery
by Erin N. McGinity, William F. Bray and Jay W. Granzow
Lymphatics 2024, 2(4), 212-227; https://doi.org/10.3390/lymphatics2040017 - 21 Oct 2024
Viewed by 1276
Abstract
Lymphedema surgeries have been proven effective in treating lymphedema and are not considered experimental or unproven. The medical literature consistently supports the safe and successful use of physiologic drainage lymphedema surgeries such as lymphaticovenous anastomosis (LVA), vascularized lymph node transfer (VLNT), and reductive [...] Read more.
Lymphedema surgeries have been proven effective in treating lymphedema and are not considered experimental or unproven. The medical literature consistently supports the safe and successful use of physiologic drainage lymphedema surgeries such as lymphaticovenous anastomosis (LVA), vascularized lymph node transfer (VLNT), and reductive surgeries such as suction-assisted protein lipectomy (SAPL) when performed by an experienced lymphedema surgery team to treat properly selected patients. Proper integration of lymphedema therapy is critical to achieving successful outcomes. We review effective lymphedema surgeries, their indications, patient selection, and the proper application of surgical treatments to achieve optimal results. Full article
Show Figures

Figure 1

17 pages, 7781 KiB  
Article
Lymphovascular Tumoral Emboli in Inflammatory Breast Cancer Result from Haptotaxis-Mediated Encircling Lymphangiogenesis
by Justin Wang, Robert M. Hoffman, Yin Ye, Jordan Dillard and Sanford H. Barsky
Lymphatics 2024, 2(4), 195-211; https://doi.org/10.3390/lymphatics2040016 - 8 Oct 2024
Viewed by 1510
Abstract
Inflammatory breast cancer (IBC) is characterized by numerous tumor emboli within lymphatics. In a recent study, we observed tumor embolic budding both in vitro and in vivo within lymphovascular spaces and proposed this to account for the plethora of tumor emboli seen in [...] Read more.
Inflammatory breast cancer (IBC) is characterized by numerous tumor emboli within lymphatics. In a recent study, we observed tumor embolic budding both in vitro and in vivo within lymphovascular spaces and proposed this to account for the plethora of tumor emboli seen in IBC. These observations did not address, however, how lymphovascular invasion is initiated or the mechanisms involved. In the present study, using the well-characterized patient-derived xenograft (PDX), Mary-X, which exhibited florid lymphovascular invasion (LVI) in athymic mice (LVI) as defined by E-cadherin-positive tumor emboli within lymphatic channels distinguished by podoplanin and LYVE1 membrane and Prox1 nuclear immunoreactivities and spontaneous spheroidgenesis in vitro and human cases of IBC which showed similar LVI, we compared laser-captured microdissected emboli from Mary-X and from the cases of human IBC to non-embolic areas. Mary-X and IBC emboli expressed high levels of E-cadherin and no evidence of epithelial–mesenchymal transition (EMT). Mary-X spheroids expressed high levels of VEGF, especially VEGF-C, and stimulated both vascular and lymphatic endothelial haptotaxis. We then transplanted Mary-X serially into green, cyano, red, and nestin-green fluorescing protein (GFP-, CFP-, RFP-, and nestin-GFP) transgenic reporter mice in various combinations. Multicolor murine imaging studies indicated that reporter-labeled stroma initially encircled clumps of tumor cells and then served as a scaffold that supported nestin-GFP-labeled endothelial haptotaxis resulting in encircling lymphangiogenesis, confirmed by dual LYVE1 immunofluorescence. The present studies demonstrate a possible mechanism of a critical step of the tumor emboli formation of IBC. Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop